Additionally, ezetimibe, the only existing NPC1L1 inhibitor, has been shown to improve lipid profiles and reduce liver injury markers in both animal models and patients with NAFLD [15,16]. The gene discussed is NPC1L1; the disease is metabolic dysfunction-associated steatotic liver disease.